Under new Medicare rules, dementia patients can’t get Aduhelm unless they have a mild form of the disease, and are participants in a drug trial. The ruling puts the $28,000-a-year drug — the only Alzheimer’s treatment — out of reach for most Americans.
Alzheimer’s patient Vance Seagle, 77, cuddles with his Yorkie dogs GG, left, and Bitsy in his suburban Cincinnati home. Seagle is in a clinical trial testing the Alzheimer’s drug Aduhelm. Changes in federal rules mean that Medicare will pay for Aduhelm only for patients who are participating in Aduhelm drug trials.
But when he’s off the drug, the former CEO tries to leave his suburban Cincinnati house in his pajamas, convinced he’s late for an important business meeting. Note to readers: if you purchase something through one of our affiliate links we may earn a commission.